Calcineurin/NFAT-Induced Up-Regulation of the Fas Ligand/Fas Death Pathway Is Involved in Methamphetamine-Induced Neuronal Apoptosis

Methamphetamine [METH ("speed")] is an abused psychostimulant that can cause psychotic, cognitive, and psychomotor impairment in humans. These signs and symptoms are thought to be related to dysfunctions in basal ganglionic structures of the brain. To identify possible molecular bases for...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 102; no. 3; pp. 868 - 873
Main Authors Jayanthi, Subramaniam, Deng, Xiaolin, Ladenheim, Bruce, McCoy, Michael T., Cluster, Andrew, Cai, Ning-Sheng, Cadet, Jean Lud, Hökfelt, Tomas
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 18.01.2005
National Acad Sciences
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Methamphetamine [METH ("speed")] is an abused psychostimulant that can cause psychotic, cognitive, and psychomotor impairment in humans. These signs and symptoms are thought to be related to dysfunctions in basal ganglionic structures of the brain. To identify possible molecular bases for these clinical manifestations, we first used cDNA microarray technology to measure METH-induced transcriptional responses in the striatum of rats treated with an apoptosis-inducing dose of the drug. METH injection resulted in increased expression of members of the Jun, Egr, and Nur77 subfamilies of transcription factors (TFs), changes that were confirmed by quantitative PCR. Because pathways linked to these factors are involved in the up-regulation of Fas ligand (FasL), FasL mRNA was quantified and found to be increased. Immunohistochemical studies also revealed METH-induced increased FasL protein expression in striatal GABAergic neurons that express enkephalin. Moreover, there were METH-mediated increases in calcineurin, as well as shuttling of nuclear factor of activated T cells (NFAT)c3 and NFATc4 from the cytosol to the nucleus of METH-treated rats, mechanisms also known to be involved in FasL regulation. Furthermore, METH induced cleavage of caspase-3 in FasL- and Fas-containing neurons. Finally, the METH-induced changes in the FasL-Fas death pathway were attenuated by pretreatment with the dopamine D1 receptor antagonist, SCH23390, which also caused attenuation of METH-induced apoptosis. These observations indicate that METH causes some of its neurodegenerative effects, in part, via stimulation of the Fas-mediated cell death pathway consequent to FasL up-regulation mediated by activation of multiple TFs.
AbstractList Methamphetamine [METH (“speed”)] is an abused psychostimulant that can cause psychotic, cognitive, and psychomotor impairment in humans. These signs and symptoms are thought to be related to dysfunctions in basal ganglionic structures of the brain. To identify possible molecular bases for these clinical manifestations, we first used cDNA microarray technology to measure METH-induced transcriptional responses in the striatum of rats treated with an apoptosis-inducing dose of the drug. METH injection resulted in increased expression of members of the Jun, Egr, and Nur77 subfamilies of transcription factors (TFs), changes that were confirmed by quantitative PCR. Because pathways linked to these factors are involved in the up-regulation of Fas ligand (FasL), FasL mRNA was quantified and found to be increased. Immunohistochemical studies also revealed METH-induced increased FasL protein expression in striatal GABAergic neurons that express enkephalin. Moreover, there were METH-mediated increases in calcineurin, as well as shuttling of nuclear factor of activated T cells (NFAT)c3 and NFATc4 from the cytosol to the nucleus of METH-treated rats, mechanisms also known to be involved in FasL regulation. Furthermore, METH induced cleavage of caspase-3 in FasL- and Fas-containing neurons. Finally, the METH-induced changes in the FasL-Fas death pathway were attenuated by pretreatment with the dopamine D1 receptor antagonist, SCH23390, which also caused attenuation of METH-induced apoptosis. These observations indicate that METH causes some of its neurodegenerative effects, in part, via stimulation of the Fas-mediated cell death pathway consequent to FasL up-regulation mediated by activation of multiple TFs.
Methamphetamine [METH ("speed")] is an abused psychostimulant that can cause psychotic, cognitive, and psychomotor impairment in humans. These signs and symptoms are thought to be related to dysfunctions in basal ganglionic structures of the brain. To identify possible molecular bases for these clinical manifestations, we first used cDNA microarray technology to measure METH-induced transcriptional responses in the striatum of rats treated with an apoptosis-inducing dose of the drug. METH injection resulted in increased expression of members of the Jun, Egr, and Nur77 subfamilies of transcription factors (TFs), changes that were confirmed by quantitative PCR. Because pathways linked to these factors are involved in the up-regulation of Fas ligand (FasL), FasL mRNA was quantified and found to be increased. Immunohistochemical studies also revealed METH-induced increased FasL protein expression in striatal GABAergic neurons that express enkephalin. Moreover, there were METH-mediated increases in calcineurin, as well as shuttling of nuclear factor of activated T cells (NFAT)c3 and NFATc4 from the cytosol to the nucleus of METH-treated rats, mechanisms also known to be involved in FasL regulation. Furthermore, METH induced cleavage of caspase-3 in FasL- and Fas-containing neurons. Finally, the METH-induced changes in the FasL-Fas death pathway were attenuated by pretreatment with the dopamine D1 receptor antagonist, SCH23390 which also caused attenuation of METH-induced apoptosis. These observations indicate that METH causes some of its neurodegenerative effects, in part, via stimulation of the Fas-mediated cell death pathway consequent to FasL up-regulation mediated by activation of multiple TFs.[PUBLICATION ABSTRACT]
Methamphetamine [METH (“speed”)] is an abused psychostimulant that can cause psychotic, cognitive, and psychomotor impairment in humans. These signs and symptoms are thought to be related to dysfunctions in basal ganglionic structures of the brain. To identify possible molecular bases for these clinical manifestations, we first used cDNA microarray technology to measure METH-induced transcriptional responses in the striatum of rats treated with an apoptosis-inducing dose of the drug. METH injection resulted in increased expression of members of the Jun, Egr, and Nur77 subfamilies of transcription factors (TFs), changes that were confirmed by quantitative PCR. Because pathways linked to these factors are involved in the up-regulation of Fas ligand (FasL), FasL mRNA was quantified and found to be increased. Immunohistochemical studies also revealed METH-induced increased FasL protein expression in striatal GABAergic neurons that express enkephalin. Moreover, there were METH-mediated increases in calcineurin, as well as shuttling of nuclear factor of activated T cells (NFAT)c3 and NFATc4 from the cytosol to the nucleus of METH-treated rats, mechanisms also known to be involved in FasL regulation. Furthermore, METH induced cleavage of caspase-3 in FasL- and Fas-containing neurons. Finally, the METH-induced changes in the FasL-Fas death pathway were attenuated by pretreatment with the dopamine D1 receptor antagonist, SCH23390, which also caused attenuation of METH-induced apoptosis. These observations indicate that METH causes some of its neurodegenerative effects, in part, via stimulation of the Fas-mediated cell death pathway consequent to FasL up-regulation mediated by activation of multiple TFs. calcium neurodegeneration gelsolin Egr
Author Cadet, Jean Lud
Hökfelt, Tomas
Jayanthi, Subramaniam
Ladenheim, Bruce
Cai, Ning-Sheng
Deng, Xiaolin
McCoy, Michael T.
Cluster, Andrew
AuthorAffiliation Molecular Neuropsychiatry Branch, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Department of Health and Human Services, 5500 Nathan Shock Drive, Baltimore, MD 21224
AuthorAffiliation_xml – name: Molecular Neuropsychiatry Branch, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Department of Health and Human Services, 5500 Nathan Shock Drive, Baltimore, MD 21224
Author_xml – sequence: 1
  givenname: Subramaniam
  surname: Jayanthi
  fullname: Jayanthi, Subramaniam
– sequence: 2
  givenname: Xiaolin
  surname: Deng
  fullname: Deng, Xiaolin
– sequence: 3
  givenname: Bruce
  surname: Ladenheim
  fullname: Ladenheim, Bruce
– sequence: 4
  givenname: Michael T.
  surname: McCoy
  fullname: McCoy, Michael T.
– sequence: 5
  givenname: Andrew
  surname: Cluster
  fullname: Cluster, Andrew
– sequence: 6
  givenname: Ning-Sheng
  surname: Cai
  fullname: Cai, Ning-Sheng
– sequence: 7
  givenname: Jean Lud
  surname: Cadet
  fullname: Cadet, Jean Lud
– sequence: 8
  givenname: Tomas
  surname: Hökfelt
  fullname: Hökfelt, Tomas
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15644446$$D View this record in MEDLINE/PubMed
BookMark eNqFks9v0zAUxy00xLrBmQugiAO3rHZsx_aBQ1VWqFQGQtvZchKnSeXaWeyU7c4fjqNW7eAAlmVbep_v--H3LsCZdVYD8BrBKwQZnnZW-StIIBECIpg9AxMEBUpzIuAZmECYsZSTjJyDC-83EEJBOXwBzhHNSVz5BPyaK1O2Vg99a6c3i9lturTVUOoquevSH3o9GBVaZxNXJ6HRyUL5ZNWula2m4_OTVqFJvsfjp3pMlj5Z2p0zu6hubfJVh0Ztu0YHtY0Rjo5vYjBnlUlmneuC861_CZ7Xynj96nBfgrvF9e38S7r69nk5n63SknIe0pqigpei5jkjVUHqvCjKIi9isaIUSKhMESRKKApMsEYIKq1phjllOcUcx30JPu79dkOx1VWpbeiVkV3fblX_KJ1q5Z8W2zZy7XaSEkoRjfoPB33v7gftg9y2vtTGKKvd4GXOMOOEi_-CiOUZooxF8P1f4MYNffwcLzOIsrF3KELTPVT2zvte18eMEZTjGMhxDORpDKLi3dNCT_yh708SHJUnd5nEkudc1oMxQT-ECL79Fxjtb_b2jQ-uPwIYM4IJxL8BeGvRdA
CitedBy_id crossref_primary_10_1111_jnc_12945
crossref_primary_10_1016_j_expneurol_2021_113795
crossref_primary_10_1016_j_pharmthera_2016_02_009
crossref_primary_10_1016_j_jchemneu_2020_101802
crossref_primary_10_1111_j_1471_4159_2007_4632_x
crossref_primary_10_1016_j_pneurobio_2015_09_011
crossref_primary_10_1016_j_metabol_2021_154710
crossref_primary_10_1016_j_toxlet_2008_01_005
crossref_primary_10_1155_2015_715639
crossref_primary_10_1152_physrev_00013_2006
crossref_primary_10_1371_journal_pone_0034236
crossref_primary_10_1016_j_bcp_2006_12_001
crossref_primary_10_1016_j_canlet_2012_01_042
crossref_primary_10_2174_1570162X17666190924200354
crossref_primary_10_1074_jbc_M112_419713
crossref_primary_10_1371_journal_pone_0007812
crossref_primary_10_1016_j_virol_2008_08_020
crossref_primary_10_1038_cdd_2014_141
crossref_primary_10_1371_journal_pone_0033822
crossref_primary_10_4049_jimmunol_1103794
crossref_primary_10_1007_s10571_013_9955_2
crossref_primary_10_1016_j_heares_2006_10_006
crossref_primary_10_5115_acb_23_193
crossref_primary_10_1016_j_brainres_2009_12_083
crossref_primary_10_1016_j_neulet_2019_134499
crossref_primary_10_3109_1547691X_2014_925995
crossref_primary_10_1523_JNEUROSCI_3384_09_2009
crossref_primary_10_1002_jcp_20861
crossref_primary_10_1210_me_2012_1045
crossref_primary_10_3389_fpsyt_2014_00020
crossref_primary_10_1096_fj_04_3362com
crossref_primary_10_1016_j_brainres_2013_12_028
crossref_primary_10_1016_j_plrev_2022_09_003
crossref_primary_10_1111_j_1749_6632_2009_05141_x
crossref_primary_10_1124_mol_111_074120
crossref_primary_10_1111_j_1471_4159_2008_05269_x
crossref_primary_10_1007_s10571_023_01323_x
crossref_primary_10_3389_fnbeh_2018_00023
crossref_primary_10_1007_s00213_011_2595_7
crossref_primary_10_1007_s12640_013_9413_4
crossref_primary_10_1371_journal_pone_0084665
crossref_primary_10_1007_BF03033567
crossref_primary_10_1016_j_neuint_2010_01_005
crossref_primary_10_1007_s00441_011_1207_5
crossref_primary_10_1042_CBI20090301
crossref_primary_10_18632_oncotarget_19507
crossref_primary_10_1111_j_1460_9568_2007_05980_x
crossref_primary_10_1155_2019_6712536
crossref_primary_10_1172_JCI37873
crossref_primary_10_3390_cells8101232
crossref_primary_10_1016_j_ab_2007_01_012
crossref_primary_10_1111_j_1471_4159_2007_04600_x
crossref_primary_10_1111_adb_12593
crossref_primary_10_1371_journal_pone_0016100
crossref_primary_10_1111_j_1471_4159_2005_03567_x
crossref_primary_10_1111_j_1440_0960_2006_00243_x
crossref_primary_10_3390_vaccines10020202
crossref_primary_10_1016_j_jchemneu_2020_101854
crossref_primary_10_1007_BF03033973
crossref_primary_10_1007_s11064_008_9863_x
crossref_primary_10_1111_joim_12049
crossref_primary_10_1016_j_neulet_2019_134478
crossref_primary_10_1111_j_1601_183X_2009_00522_x
crossref_primary_10_1016_j_neures_2009_06_007
crossref_primary_10_1016_j_pneurobio_2007_09_004
crossref_primary_10_1002_hup_2335
crossref_primary_10_1007_BF03033855
crossref_primary_10_1016_j_ejphar_2013_12_039
crossref_primary_10_1016_j_nbd_2011_11_005
crossref_primary_10_1038_srep29041
crossref_primary_10_1371_journal_pone_0028946
crossref_primary_10_1523_JNEUROSCI_4893_04_2005
crossref_primary_10_1111_j_1471_4159_2006_03874_x
crossref_primary_10_1073_pnas_0505138102
crossref_primary_10_1096_fj_08_113076
crossref_primary_10_1155_2015_103969
crossref_primary_10_1016_j_neuro_2014_10_008
crossref_primary_10_3389_fimmu_2023_1281882
crossref_primary_10_1080_15569543_2017_1288141
crossref_primary_10_1111_j_1471_4159_2006_03744_x
crossref_primary_10_1002_jnr_21819
crossref_primary_10_1007_s12012_013_9237_8
crossref_primary_10_1038_sj_npp_1301089
crossref_primary_10_3390_brainsci2040434
crossref_primary_10_1007_s11064_014_1454_4
crossref_primary_10_3390_brainsci2040553
crossref_primary_10_1002_jnr_20695
crossref_primary_10_1016_j_yexcr_2007_04_032
crossref_primary_10_4303_jdar_235626
crossref_primary_10_1002_syn_20285
crossref_primary_10_1016_j_expneurol_2014_01_020
crossref_primary_10_1007_s12640_013_9442_z
crossref_primary_10_1016_j_sjbs_2020_08_042
crossref_primary_10_1016_j_neuroscience_2012_09_029
crossref_primary_10_1186_s10020_023_00704_8
crossref_primary_10_1089_omi_2006_10_311
crossref_primary_10_1093_ijnp_pyz050
crossref_primary_10_3389_fphar_2022_972828
crossref_primary_10_3390_brainsci7030025
crossref_primary_10_1007_s00213_010_2146_7
crossref_primary_10_1016_j_jchemneu_2020_101793
crossref_primary_10_1016_j_jchemneu_2019_101712
crossref_primary_10_1523_JNEUROSCI_4873_09_2009
crossref_primary_10_1177_0271678X20931137
crossref_primary_10_3390_ijms25105293
crossref_primary_10_1016_j_ygeno_2008_06_011
crossref_primary_10_1111_j_1471_4159_2006_03733_x
crossref_primary_10_1007_s00204_020_02844_w
crossref_primary_10_1016_j_jad_2017_06_017
crossref_primary_10_1074_jbc_M112_365197
crossref_primary_10_1016_j_neuro_2019_12_006
crossref_primary_10_1007_BF03033915
crossref_primary_10_1016_j_taap_2018_05_031
crossref_primary_10_1016_j_bbrc_2018_03_182
crossref_primary_10_1016_j_neuro_2009_02_003
crossref_primary_10_1007_s13365_012_0103_4
crossref_primary_10_3390_cells9122609
crossref_primary_10_1111_jnc_13568
crossref_primary_10_1007_s00213_016_4235_8
crossref_primary_10_1016_j_taap_2007_01_011
crossref_primary_10_1016_j_brainresrev_2009_03_002
crossref_primary_10_1248_yakushi_131_13
crossref_primary_10_1002_jcb_20834
crossref_primary_10_1016_j_ijpsycho_2020_09_004
crossref_primary_10_1007_s12640_021_00420_3
crossref_primary_10_1196_annals_1369_002
crossref_primary_10_1111_ejn_12628
crossref_primary_10_1016_j_neuroscience_2010_08_049
crossref_primary_10_1007_s12640_017_9723_z
crossref_primary_10_1016_j_peptides_2006_07_011
crossref_primary_10_3389_fphar_2022_980340
crossref_primary_10_1007_BF03033362
crossref_primary_10_1016_j_taap_2011_04_021
crossref_primary_10_3389_fimmu_2019_01660
crossref_primary_10_1016_j_biopsych_2006_09_010
crossref_primary_10_1016_j_bbrc_2011_08_126
crossref_primary_10_1016_j_biosystems_2015_07_002
crossref_primary_10_1111_j_1745_7262_2007_00257_x
crossref_primary_10_1007_s00213_015_3914_1
crossref_primary_10_1007_s12640_009_9026_0
crossref_primary_10_1523_JNEUROSCI_1179_08_2008
crossref_primary_10_1523_JNEUROSCI_5227_07_2008
crossref_primary_10_4303_jdar_235648
crossref_primary_10_1016_j_neuroscience_2011_08_013
crossref_primary_10_1155_2018_4982453
crossref_primary_10_1155_2022_4445734
crossref_primary_10_1016_j_steroids_2011_02_013
crossref_primary_10_1016_j_lfs_2013_07_014
crossref_primary_10_1038_mp_2014_142
crossref_primary_10_1007_s12035_024_04129_0
crossref_primary_10_1016_j_expneurol_2014_09_010
crossref_primary_10_1093_hmg_ddu377
crossref_primary_10_1016_j_neuropharm_2012_01_013
crossref_primary_10_1007_s12031_016_0849_x
crossref_primary_10_1111_j_1476_5381_2010_00989_x
crossref_primary_10_1007_s13365_011_0043_4
crossref_primary_10_1073_pnas_1403493111
crossref_primary_10_1017_S1461145713000850
crossref_primary_10_4303_jdar_235998
crossref_primary_10_1007_s11373_005_9048_4
crossref_primary_10_1016_j_pneurobio_2021_102112
crossref_primary_10_1007_s12031_013_0198_y
crossref_primary_10_1016_j_jns_2011_06_038
crossref_primary_10_1371_journal_pone_0019882
crossref_primary_10_1093_carcin_bgs282
crossref_primary_10_1111_j_1471_4159_2007_04632_x
crossref_primary_10_1155_2016_5081021
crossref_primary_10_3389_fnsyn_2024_1384625
Cites_doi 10.1124/mol.62.5.993
10.1523/JNEUROSCI.21-23-09414.2001
10.1002/syn.10074
10.1056/NEJMra022366
10.1096/fj.01-0025com
10.1523/JNEUROSCI.22-09-03504.2002
10.1074/jbc.274.5.3222
10.1016/S0740-5472(02)00267-2
10.1096/fj.03-0073rev
10.1016/S0925-4927(02)00004-5
10.1176/appi.ajp.158.3.377
10.1038/365352a0
10.1146/annurev.immunol.15.1.707
10.1016/S0006-8993(00)02107-7
10.1096/fasebj.13.9.1065
10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.0.CO;2-V
10.1128/MCB.23.21.7638-7647.2003
10.1002/1521-4141(200105)31:5<1382::AID-IMMU1382>3.0.CO;2-Y
10.1523/JNEUROSCI.19-22-10107.1999
10.1007/s00702-002-0754-z
10.1016/S0092-8674(02)00699-2
10.1038/sj.cdd.4400984
10.1074/jbc.271.18.10884
10.1016/S0092-8674(01)00237-9
10.1074/jbc.271.37.22398
10.1126/science.278.5336.294
10.1002/jcp.10178
10.1016/S0952-7915(98)80223-9
10.1128/MCB.19.3.1720
10.1093/emboj/19.17.4783
10.1016/S0169-328X(98)00055-2
10.1016/S0197-0186(96)00136-2
10.1016/S0006-2952(00)00372-5
10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R
10.1016/S0169-328X(01)00184-X
10.1038/bjc.1972.33
10.1097/00126334-200312150-00004
10.1124/mol.61.5.1124
10.1016/S0028-3908(02)00034-5
10.1016/S0161-5890(01)00108-0
10.1074/jbc.274.48.34450
10.1101/gad.1102703
10.1186/gb-2003-4-9-117
10.1074/jbc.272.50.31427
10.1096/fj.03-0295com
10.1038/nm0696-699
10.1176/appi.ajp.158.3.383
10.1146/annurev.genet.33.1.29
10.1080/02791072.2000.10400221
ContentType Journal Article
Copyright Copyright 1993/2005 The National Academy of Sciences of the United States of America
Copyright National Academy of Sciences Jan 18, 2005
2005
Copyright_xml – notice: Copyright 1993/2005 The National Academy of Sciences of the United States of America
– notice: Copyright National Academy of Sciences Jan 18, 2005
– notice: 2005
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QG
7QL
7QP
7QR
7SN
7SS
7T5
7TK
7TM
7TO
7U9
8FD
C1K
FR3
H94
M7N
P64
RC3
7U7
7X8
5PM
DOI 10.1073/pnas.0404990102
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Immunology Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
Toxicology Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
Nucleic Acids Abstracts
Ecology Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Entomology Abstracts
Genetics Abstracts
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Immunology Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Toxicology Abstracts
MEDLINE - Academic
DatabaseTitleList CrossRef

Virology and AIDS Abstracts
MEDLINE


Toxicology Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
EISSN 1091-6490
EndPage 873
ExternalDocumentID 801840511
10_1073_pnas_0404990102
15644446
102_3_868
3374340
Genre Journal Article
Feature
GroupedDBID ---
-DZ
-~X
.55
.GJ
0R~
123
29P
2AX
2FS
2WC
3O-
4.4
53G
5RE
5VS
79B
85S
AACGO
AAFWJ
AANCE
AAYJJ
ABBHK
ABOCM
ABPLY
ABPPZ
ABTLG
ABXSQ
ABZEH
ACGOD
ACIWK
ACNCT
ACPRK
ADULT
ADZLD
AENEX
AEUPB
AEXZC
AFFNX
AFOSN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
AQVQM
ASUFR
AS~
BKOMP
CS3
D0L
DCCCD
DIK
DNJUQ
DOOOF
DU5
DWIUU
E3Z
EBS
EJD
F20
F5P
FRP
GX1
HH5
HQ3
HTVGU
HYE
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JSODD
JST
KQ8
L7B
LU7
MVM
N9A
NEJ
N~3
O9-
OK1
P-O
PNE
PQQKQ
R.V
RHF
RHI
RNA
RNS
RPM
RXW
SA0
SJN
TAE
TN5
UKR
VOH
VQA
W8F
WH7
WHG
WOQ
WOW
X7M
XFK
XSW
Y6R
YBH
YKV
YSK
ZA5
ZCA
ZCG
~02
~KM
-
02
0R
1AW
55
AAPBV
ABFLS
ABPTK
ADACO
AJYGW
AS
DZ
GJ
KM
OHM
PQEST
X
XHC
ADACV
CGR
CUY
CVF
ECM
EIF
H13
IPSME
NPM
AAYXX
CITATION
7QG
7QL
7QP
7QR
7SN
7SS
7T5
7TK
7TM
7TO
7U9
8FD
C1K
FR3
H94
M7N
P64
RC3
7U7
ADQXQ
7X8
5PM
ID FETCH-LOGICAL-c588t-f51b8c9f8674db4f6bbcb6b6499c919a2a419c09b343e110aee52385765383383
IEDL.DBID RPM
ISSN 0027-8424
IngestDate Tue Sep 17 21:13:07 EDT 2024
Sat Aug 17 02:23:22 EDT 2024
Fri Aug 16 10:43:36 EDT 2024
Thu Oct 10 19:09:32 EDT 2024
Fri Aug 23 00:57:22 EDT 2024
Sat Sep 28 07:44:24 EDT 2024
Wed Nov 11 00:29:33 EST 2020
Thu May 30 08:51:41 EDT 2019
Fri Feb 02 07:04:48 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c588t-f51b8c9f8674db4f6bbcb6b6499c919a2a419c09b343e110aee52385765383383
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
S.J. and X.D. contributed equally to this work.
Author contributions: J.L.C. designed research; S.J., X.D., B.L., M.T.M., A.C., and N.-s.C. performed research; S.J., X.D., B.L., A.C., and M.T.M. analyzed data; and S.J., X.D., and J.L.C. wrote the paper.
Edited by Tomas Hökfelt, Karolinska Institutet, Stockholm, Sweden, and approved December 9, 2004
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: METH, methamphetamine; DA, dopamine; TF, transcription factor; FasL, Fas ligand; ENK, enkephalin; NFAT, nuclear factor of activated T cells; SP, Substance P; GAD, glutamic acid decarboxylase; Egr, early growth response gene.
To whom correspondence should be addressed. E-mail: jcadet@intra.nida.nih.gov.
OpenAccessLink https://doi.org/10.1073/pnas.0404990102
PMID 15644446
PQID 201284241
PQPubID 42026
PageCount 6
ParticipantIDs proquest_journals_201284241
pnas_primary_102_3_868_fulltext
proquest_miscellaneous_17621577
jstor_primary_3374340
pubmedcentral_primary_oai_pubmedcentral_nih_gov_545515
proquest_miscellaneous_67378489
crossref_primary_10_1073_pnas_0404990102
pubmed_primary_15644446
pnas_primary_102_3_868
ProviderPackageCode RNA
PNE
PublicationCentury 2000
PublicationDate 2005-01-18
PublicationDateYYYYMMDD 2005-01-18
PublicationDate_xml – month: 01
  year: 2005
  text: 2005-01-18
  day: 18
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington
PublicationTitle Proceedings of the National Academy of Sciences - PNAS
PublicationTitleAlternate Proc Natl Acad Sci U S A
PublicationYear 2005
Publisher National Academy of Sciences
National Acad Sciences
Publisher_xml – name: National Academy of Sciences
– name: National Acad Sciences
References 9685645 - Brain Res Mol Brain Res. 1998 Jul 15;58(1-2):209-16
12672865 - N Engl J Med. 2003 Apr 3;348(14):1365-75
10773198 - Brain Res. 2000 Apr 28;863(1-2):106-11
11983154 - Cell. 2002 Apr;109 Suppl:S67-79
12384981 - J Cell Physiol. 2002 Dec;193(3):287-92
11239407 - Cell. 2001 Feb 23;104(4):487-501
9323209 - Science. 1997 Oct 10;278(5336):294-8
11532339 - Brain Res Mol Brain Res. 2001 Sep 10;93(1):64-9
11978827 - J Neurosci. 2002 May 1;22(9):3504-11
10022859 - Mol Cell Biol. 1999 Mar;19(3):1720-30
14519657 - FASEB J. 2003 Oct;17(13):1775-88
9307998 - Neurochem Int. 1997 Oct;31(4):477-510; discussion 517-6
12203042 - J Neural Transm (Vienna). 2002 Sep;109(9):1151-8
14769818 - FASEB J. 2004 Feb;18(2):238-51
11961130 - Mol Pharmacol. 2002 May;61(5):1124-31
12015210 - Neuropharmacology. 2002 May;42(6):837-45
11984857 - Synapse. 2002 Jun 15;44(4):211-26
11229977 - Am J Psychiatry. 2001 Mar;158(3):377-82
12975316 - Genes Dev. 2003 Sep 15;17(18):2205-32
9143705 - Annu Rev Immunol. 1997;15:707-47
8798402 - J Biol Chem. 1996 Sep 13;271(37):22398-406
12391261 - Mol Pharmacol. 2002 Nov;62(5):993-1000
11717374 - J Neurosci. 2001 Dec 1;21(23):9414-8
14657756 - J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):467-74
11840160 - Cell Death Differ. 2002 Feb;9(2):101-3
4561027 - Br J Cancer. 1972 Aug;26(4):239-57
11007936 - Biochem Pharmacol. 2000 Oct 15;60(8):1015-21
11465095 - Eur J Immunol. 2001 May;31(5):1382-91
12036507 - Psychiatry Res. 2002 Jun 15;114(2):65-79
8640565 - Nat Med. 1996 Jun;2(6):699-703
11229978 - Am J Psychiatry. 2001 Mar;158(3):383-9
11481222 - FASEB J. 2001 Aug;15(10):1745-52
9776136 - Synapse. 1998 Nov;30(3):329-33
10970869 - EMBO J. 2000 Sep 1;19(17):4783-95
14560009 - Mol Cell Biol. 2003 Nov;23(21):7638-47
10336889 - FASEB J. 1999 Jun;13(9):1065-72
10690403 - Annu Rev Genet. 1999;33:29-55
9794838 - Curr Opin Immunol. 1998 Oct;10(5):552-8
12952525 - Genome Biol. 2003;4(9):117
10567426 - J Biol Chem. 1999 Nov 26;274(48):34450-8
8631904 - J Biol Chem. 1996 May 3;271(18):10884-91
8397339 - Nature. 1993 Sep 23;365(6444):352-5
10559418 - J Neurosci. 1999 Nov 15;19(22):10107-15
9395475 - J Biol Chem. 1997 Dec 12;272(50):31427-34
10908000 - J Psychoactive Drugs. 2000 Apr-Jun;32(2):137-41
9915863 - J Biol Chem. 1999 Jan 29;274(5):3222-7
10508276 - Eur J Immunol. 1999 Sep;29(9):3017-27
12220613 - J Subst Abuse Treat. 2002 Sep;23(2):151-6
11841831 - Mol Immunol. 2002 Feb;38(10):713-21
e_1_3_1_43_2
e_1_3_1_22_2
e_1_3_1_45_2
e_1_3_1_24_2
e_1_3_1_8_2
e_1_3_1_41_2
e_1_3_1_20_2
e_1_3_1_4_2
e_1_3_1_6_2
e_1_3_1_26_2
e_1_3_1_47_2
e_1_3_1_2_2
e_1_3_1_28_2
e_1_3_1_49_2
e_1_3_1_32_2
e_1_3_1_34_2
e_1_3_1_13_2
e_1_3_1_11_2
e_1_3_1_30_2
e_1_3_1_17_2
e_1_3_1_15_2
e_1_3_1_36_2
e_1_3_1_19_2
e_1_3_1_38_2
e_1_3_1_21_2
e_1_3_1_44_2
e_1_3_1_23_2
e_1_3_1_46_2
e_1_3_1_7_2
e_1_3_1_40_2
e_1_3_1_9_2
e_1_3_1_42_2
e_1_3_1_29_2
e_1_3_1_3_2
e_1_3_1_5_2
e_1_3_1_25_2
e_1_3_1_48_2
e_1_3_1_27_2
e_1_3_1_1_2
e_1_3_1_33_2
e_1_3_1_35_2
e_1_3_1_12_2
e_1_3_1_50_2
e_1_3_1_10_2
e_1_3_1_31_2
e_1_3_1_16_2
e_1_3_1_14_2
e_1_3_1_37_2
e_1_3_1_18_2
e_1_3_1_39_2
References_xml – ident: e_1_3_1_16_2
  doi: 10.1124/mol.62.5.993
– ident: e_1_3_1_7_2
  doi: 10.1523/JNEUROSCI.21-23-09414.2001
– ident: e_1_3_1_21_2
  doi: 10.1002/syn.10074
– ident: e_1_3_1_46_2
  doi: 10.1056/NEJMra022366
– ident: e_1_3_1_15_2
  doi: 10.1096/fj.01-0025com
– ident: e_1_3_1_30_2
  doi: 10.1523/JNEUROSCI.22-09-03504.2002
– ident: e_1_3_1_34_2
  doi: 10.1074/jbc.274.5.3222
– ident: e_1_3_1_2_2
  doi: 10.1016/S0740-5472(02)00267-2
– ident: e_1_3_1_6_2
  doi: 10.1096/fj.03-0073rev
– ident: e_1_3_1_9_2
  doi: 10.1016/S0925-4927(02)00004-5
– ident: e_1_3_1_4_2
  doi: 10.1176/appi.ajp.158.3.377
– ident: e_1_3_1_39_2
  doi: 10.1038/365352a0
– ident: e_1_3_1_35_2
  doi: 10.1146/annurev.immunol.15.1.707
– ident: e_1_3_1_19_2
  doi: 10.1016/S0006-8993(00)02107-7
– ident: e_1_3_1_12_2
  doi: 10.1096/fasebj.13.9.1065
– ident: e_1_3_1_14_2
  doi: 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.0.CO;2-V
– ident: e_1_3_1_26_2
  doi: 10.1128/MCB.23.21.7638-7647.2003
– ident: e_1_3_1_31_2
  doi: 10.1002/1521-4141(200105)31:5<1382::AID-IMMU1382>3.0.CO;2-Y
– ident: e_1_3_1_13_2
  doi: 10.1523/JNEUROSCI.19-22-10107.1999
– ident: e_1_3_1_3_2
  doi: 10.1007/s00702-002-0754-z
– ident: e_1_3_1_36_2
  doi: 10.1016/S0092-8674(02)00699-2
– ident: e_1_3_1_28_2
  doi: 10.1038/sj.cdd.4400984
– ident: e_1_3_1_40_2
  doi: 10.1074/jbc.271.18.10884
– ident: e_1_3_1_29_2
  doi: 10.1016/S0092-8674(01)00237-9
– ident: e_1_3_1_44_2
  doi: 10.1074/jbc.271.37.22398
– ident: e_1_3_1_43_2
  doi: 10.1126/science.278.5336.294
– ident: e_1_3_1_25_2
  doi: 10.1002/jcp.10178
– ident: e_1_3_1_48_2
  doi: 10.1016/S0952-7915(98)80223-9
– ident: e_1_3_1_49_2
  doi: 10.1128/MCB.19.3.1720
– ident: e_1_3_1_33_2
  doi: 10.1093/emboj/19.17.4783
– ident: e_1_3_1_22_2
  doi: 10.1016/S0169-328X(98)00055-2
– ident: e_1_3_1_24_2
  doi: 10.1016/S0197-0186(96)00136-2
– ident: e_1_3_1_23_2
  doi: 10.1016/S0006-2952(00)00372-5
– ident: e_1_3_1_27_2
  doi: 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R
– ident: e_1_3_1_20_2
  doi: 10.1016/S0169-328X(01)00184-X
– ident: e_1_3_1_45_2
  doi: 10.1038/bjc.1972.33
– ident: e_1_3_1_10_2
  doi: 10.1097/00126334-200312150-00004
– ident: e_1_3_1_17_2
  doi: 10.1124/mol.61.5.1124
– ident: e_1_3_1_11_2
  doi: 10.1016/S0028-3908(02)00034-5
– ident: e_1_3_1_38_2
  doi: 10.1016/S0161-5890(01)00108-0
– ident: e_1_3_1_41_2
  doi: 10.1074/jbc.274.48.34450
– ident: e_1_3_1_37_2
  doi: 10.1101/gad.1102703
– ident: e_1_3_1_50_2
  doi: 10.1186/gb-2003-4-9-117
– ident: e_1_3_1_32_2
  doi: 10.1074/jbc.272.50.31427
– ident: e_1_3_1_18_2
  doi: 10.1096/fj.03-0295com
– ident: e_1_3_1_5_2
  doi: 10.1038/nm0696-699
– ident: e_1_3_1_8_2
  doi: 10.1176/appi.ajp.158.3.383
– ident: e_1_3_1_42_2
  doi: 10.1146/annurev.genet.33.1.29
– ident: e_1_3_1_47_2
– ident: e_1_3_1_1_2
  doi: 10.1080/02791072.2000.10400221
SSID ssj0009580
Score 2.3127384
Snippet Methamphetamine [METH ("speed")] is an abused psychostimulant that can cause psychotic, cognitive, and psychomotor impairment in humans. These signs and...
Methamphetamine [METH (“speed”)] is an abused psychostimulant that can cause psychotic, cognitive, and psychomotor impairment in humans. These signs and...
SourceID pubmedcentral
proquest
crossref
pubmed
pnas
jstor
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 868
SubjectTerms Active Transport, Cell Nucleus - drug effects
Animals
Antibodies
Apoptosis
Apoptosis - drug effects
Biological Sciences
Brain
Calcineurin
Calcium
Cell death
Cell membranes
Corpus Striatum - metabolism
DNA-Binding Proteins - metabolism
Dosage
Fas Ligand Protein
fas Receptor - metabolism
Male
Membrane Glycoproteins - metabolism
Messenger RNA
Methamphetamine
Methamphetamine - pharmacology
Nerve Tissue Proteins - metabolism
Neurology
Neurons
Neurons - cytology
Neurons - drug effects
Neurons - metabolism
NFATC Transcription Factors
Nuclear Proteins - metabolism
Rats
Rats, Sprague-Dawley
T lymphocytes
Transcription Factors - genetics
Transcription Factors - metabolism
Transcription, Genetic - drug effects
Up regulation
Title Calcineurin/NFAT-Induced Up-Regulation of the Fas Ligand/Fas Death Pathway Is Involved in Methamphetamine-Induced Neuronal Apoptosis
URI https://www.jstor.org/stable/3374340
http://www.pnas.org/content/102/3/868.abstract
https://www.ncbi.nlm.nih.gov/pubmed/15644446
https://www.proquest.com/docview/201284241
https://search.proquest.com/docview/17621577
https://search.proquest.com/docview/67378489
https://pubmed.ncbi.nlm.nih.gov/PMC545515
Volume 102
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3BbtQwELVoT1wQhRZCafGBQzl4E8dOYh-rFasCouLQSr1FtuNApF0nanZB3Pnwjp1kt0Xlwi2Sx4mVmfG8iSdvEHrPqNK55ZQUlUkIZ4UmKuMFqQWvmOUi4TYUyF7mF9f88012M_4U1o9llc7oZuaWq5lrfoTaym5l4qlOLP72dQ5RH8JwvIf2CsamDH1LtCuG305S2H15yic6n4LFnVP9DIyW-7OgJPSxyQAOcA9-7wWloS7Rk52C_GPA8-_6yXsBafEcPRuRJD4fVnyAnlj3Ah2Mvtrjs5FQ-sNL9Geulv783H9Yjy8X51cEEnFQaYU3HbkdmtGDenBbY4CDeKF6vGy-K1fF_rLyIBH7zsW_1G_c9LhxsKX9hNmNw74BtQKDsGu1gidsbxxoMv3yVNd267Zv-kN0vfh4Nb8gY_cFYjIh1qTOqBZG1iIveKV5nWttdK5zeHtGUqlSxak0idSMMwsgQlkLSa2A_AX2UJ_4HqF91zr7GmEhjZFKyVSDCWRMS8gqaaUlT6paA2KI0Nn0-stuINkow-F4wUqvhHKntAgdBvVs5RgDDMSTCB0Fyd30tGSlyOHe7x4fKOuxuiZCx5OKy9GB-zINgRvgjZ8_jYLn-eMU5Wy76UsKcYRmRfFvCd8DSHAhI_RqMJjdKkbDi1D-wJS2Ap71--EIOENg_x6M_83_TjxGTwP7bEIJFW_R_vp2Y08AV631KWQUn76cBne6A4J5JBg
link.rule.ids 230,315,733,786,790,891,27955,27956,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLZgHOACDDYIA-YDh3FI88NOYh-niqrAVnFopd0s23FGRJtGSwqCM384z07SbtM4wK2Sn9NE77Pf9-KX7yH0jkRSpYZGfpbr0KckU75MaOYXjObEUBZS4wpkZ-l0QT9dJBf9R2FNX1ZZaVWOquVqVJVfXW1lvdLBUCcWfDkfQ9SHMBzcRw9gucbJkKNvpXZZ9-FJDPsvjekg6JORoK5kMwLYUnsaFLpONgkQAmrp77Ww1FUmWrlTsL-Let6uoLwWkiZP0GJ4mK4S5dto06qR_nVL5_Ffn_YpetxzVHzaje6je6Z6hvb7XaDBJ71U9fvn6PdYLu3JvH1lH8wmp3MfUnwAS443tX_VtbkHx-N1gYFo4ols8LK8lFUe2J-5pZ_Y9kT-IX_issFlBZvld5hdVti2tpYANdPKFfzD9sJOgNPenqzXdbtuyuYALSYf5uOp3_d18HXCWOsXSaSY5gVLM5orWqRKaZWqFLyiecRlLGnEdcgVocQAPZHGQLrMIDMCd9uU-hDtVevKvESYca25lDxWAK6EKA75apQrTsO8UMBFPHQyuFXUnXyHcMfuGRHWuWIHBg8dOLdv7QgBdkVDDx06y930WBDBUrj28d0Doujrdjx0NEBH9FtDI2JHCYA42fnDKKxpe1AjK7PeNCKCCBUlWfZ3C9tdiFHGPfSiA-LuLnpAeyi9AdGtgdUTvzkCwHO64h3QXv3vxGP0cDo_PxNnH2efj9Ajp3EbRn7EXqO99mpj3gB7a9Vbt1j_ALV9RN0
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKkRAXoNBCKFAfOJRDNh92EvtYLazK16qHViony3acErGbRE0WBGd-OGMn2W2rcultJY-ziebZ8yaevEHoLYmkSg2N_CzXoU9JpnyZ0MwvGM2JoSykxhXIztPjM_rpPDnfQmz8FsYV7WtVTqrFclKV311tZbPUwVgnFpx8nULUhzAcNHkR3EP3YcnG2Zinr-V2Wf_xSQx7MI3pKOqTkaCpZDsB6FJ7IhS6bjYJkAJqKfCV0NRXJ1rJU7C_jX7erKK8EpZmj9G38YH6apQfk1WnJvrPDa3HuzzxE_Ro4Kr4qLfYQVumeop2ht2gxYeDZPW7Z-jvVC7sCb19dR_MZ0enPqT6AJocrxr_sm93DwDAdYGBcOKZbPGivJBVHtifuaWh2PZG_iV_47LFZQWb5k-YXVbYtriWADnTySX8w_rCTojT3p5s6qar27LdRWezD6fTY3_o7-DrhLHOL5JIMc0LlmY0V7RIldIqVSl4RvOIy1jSiOuQK0KJAZoijYG0mUGGBC63qfUe2q7qyrxAmHGtuZQ8VgCyhCgOeWuUK07DvFDASTx0OLpWNL2Mh3DH7xkR1sFiAwgP7TrXr-0IAZZFQw_tOcvN9FgQwVK49sHtA6IY6nc8tD_CRwxbRCtiRw2AQNn54yisbXtgIytTr1oRQaSKkiz7v4XtMsQo4x563oNxcxcDqD2UXoPp2sDqil8fAfA5ffEebC_vOvEAPTh5PxNfPs4_76OHTuo2jPyIvULb3eXKvAYS16k3br3-A8LwR10
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Calcineurin%2FNFAT-induced+up-regulation+of+the+Fas+ligand%2FFas+death+pathway+is+involved+in+methamphetamine-induced+neuronal+apoptosis&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Jayanthi%2C+Subramaniam&rft.au=Deng%2C+Xiaolin&rft.au=Ladenheim%2C+Bruce&rft.au=McCoy%2C+Michael+T&rft.date=2005-01-18&rft.issn=0027-8424&rft.volume=102&rft.issue=3&rft.spage=868&rft_id=info:doi/10.1073%2Fpnas.0404990102&rft_id=info%3Apmid%2F15644446&rft.externalDocID=15644446
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F102%2F3.cover.gif
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F102%2F3.cover.gif